Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Shingo Yanagi"'
Autor:
Rimi Izumihara, Hiroshi Nomoto, Kenichi Kito, Yuki Yamauchi, Kazuno Omori, Yui Shibayama, Shingo Yanagiya, Aika Miya, Hiraku Kameda, Kyu Yong Cho, So Nagai, Ichiro Sakuma, Akinobu Nakamura, Tatsuya Atsumi
Publikováno v:
Diabetes & Metabolism Journal, Vol 48, Iss 3, Pp 473-481 (2024)
Background Fibrates have renal toxicity limiting their use in subjects with chronic kidney disease (CKD). However, pemafibrate has fewer toxic effects on renal function. In the present analysis, we evaluated the effects of pemafibrate on the renal fu
Externí odkaz:
https://doaj.org/article/434fc40dd96546bfba539ebd70216bbd
Autor:
Hiroshi Nomoto, Kenichi Kito, Hiroshi Iesaka, Takahisa Handa, Shingo Yanagiya, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Jun Takeuchi, So Nagai, Ichiro Sakuma, Akinobu Nakamura, Tatsuya Atsumi
Publikováno v:
Diabetology & Metabolic Syndrome, Vol 15, Iss 1, Pp 1-6 (2023)
Abstract Background Pemafibrate has been reported to ameliorate lipid profiles and liver dysfunction. However, which patients derive benefit from the hepatoprotective effects of pemafibrate is unclear. Methods We conducted a sub-analysis of the PARM-
Externí odkaz:
https://doaj.org/article/5bb4852fbbde4581be2db141350d4fa6
Autor:
Atsushi Ochiai, Kanji Nagai, Genichiro Ishii, Motohiro Kojima, Kiyotaka Yoh, Keiju Aokage, Shingo Yanagi, Yutaka Nishiwaki, Yoko Yamaguchi, Hajime Otsuka, Yoichi Otaki
Publikováno v:
Journal of Thoracic Oncology. 5(9):1361-1368
IntroductionThe term tumor budding has been applied to single cells or small clusters of up to four cells within the stromal tissue at the invasive margin of colorectal cancers. This morphologic feature is increasingly being recognized as an adverse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f91e2a2b1f37dbff6fb477655a956dbd
Autor:
Kyu Yong Cho, Hiroshi Nomoto, Akinobu Nakamura, Shinichiro Kawata, Hajime Sugawara, Jun Takeuchi, So Nagai, Kazuno Omori, Kazuhisa Tsuchida, Aika Miya, Ikumi Shigesawa, Kenichi Tsuchida, Shingo Yanagiya, Hiraku Kameda, Hiroki Yokoyama, Shinji Taneda, Yoshio Kurihara, Shin Aoki, Naoki Nishimoto, Tatsuya Atsumi, Hideaki Miyoshi
Publikováno v:
Journal of Diabetes Investigation, Vol 12, Iss 8, Pp 1417-1424 (2021)
Abstract Aims/Introduction We recently reported the beneficial effect of the combination of sodium–glucose cotransporter 2 inhibitor and dipeptidyl peptidase‐4 inhibitor on daily glycemic variability in patients with type 2 diabetes mellitus. Add
Externí odkaz:
https://doaj.org/article/3e8bdc46ba6e43f5ae3287bfe8db2f38
Autor:
Hiroshi Nomoto, Kenichi Kito, Hiroshi Iesaka, Yuki Oe, Shinichiro Kawata, Kazuhisa Tsuchida, Shingo Yanagiya, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Ichiro Sakuma, Naoki Manda, Akinobu Nakamura, Tatsuya Atsumi
Publikováno v:
Pharmaceutics, Vol 15, Iss 7, p 1838 (2023)
Pemafibrate, a novel selective peroxisome proliferator-activated receptor modulator, has beneficial effects on lipid metabolism. However, its effects on glucose metabolism in individuals with type 2 diabetes (T2DM) remain to be fully clarified. This
Externí odkaz:
https://doaj.org/article/bce99a07c18e4315a46c76fa01e690bc
Autor:
Kyu Yong Cho, Akinobu Nakamura, Chiho Oba-Yamamoto, Kazuhisa Tsuchida, Shingo Yanagiya, Naoki Manda, Yoshio Kurihara, Shin Aoki, Tatsuya Atsumi, Hideaki Miyoshi
Publikováno v:
Diabetes & Metabolism Journal, Vol 44, Iss 4, Pp 532-541 (2020)
BackgroundTo explore the efficacy and safety of switching from once-daily basal insulin therapy to once-daily pre-meal injection insulin degludec/insulin aspart (IDegAsp) with respect to the glycemic control of participants with type 2 diabetes melli
Externí odkaz:
https://doaj.org/article/0405fcef939e4d59869fb1b6eeeddd9c
Autor:
Hiroshi Nomoto, Hideaki Miyoshi, Hajime Sugawara, Kota Ono, Shingo Yanagiya, Mayuko Oita, Akinobu Nakamura, Tatsuya Atsumi
Publikováno v:
Diabetology & Metabolic Syndrome, Vol 9, Iss 1, Pp 1-9 (2017)
Abstract Background Dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium–glucose co-transporter 2 (SGLT2) inhibitors improve hyperglycemia, and the usefulness of co-administration of DPP-4 inhibitors and insulin therapy has been well established. H
Externí odkaz:
https://doaj.org/article/f46160405fc5499fb37d69145db29795